Abion

Abion ROCE

The Return on Capital Employed (ROCE) of Abion (203400.KQ) as of Oct 22, 2026 is -34.82 %. In the previous year, Return on Capital Employed (ROCE) was -143.11 % — a change of -75.67% (higher).

ROCE

-34.82 %

YoY

-75.67%

Last updated:

In 2025, Abion's return on capital employed (ROCE) was -34.82 %, a -75.67% increase from the -143.11 % ROCE in the previous year.

The Abion ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2017
-354.41 KRW
Jan 1, 2018
-325.48 KRW
Jan 1, 2019
83.05 KRW
Jan 1, 2020
48.45 KRW
Jan 1, 2022
-168.32 KRW
Jan 1, 2023
-313.16 KRW
Jan 1, 2024
-143.11 KRW
Jan 1, 2025
-34.82 KRW
The Abion ROCE history
YEARROCEYoY
-34.82 %-75.67%
-143.11 %-54.30%
-313.16 %+86.05%
-168.32 %-447.43%
48.45 %-41.67%
83.05 %-125.52%
-325.48 %-8.16%
-354.41 %+165.40%
-133.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Abion Stock analysis

What does Abion do? ABION, Inc. generates revenue through its Product segment, which sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment offers histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services to clients in the biopharmaceutical industry. The Research segment focuses on developing drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics, with potential future commercialization. The company's business model relies on these four segments to serve biopharmaceutical companies seeking innovative diagnostic tools and therapeutic solutions. The Product segment targets biopharmaceutical firms requiring laboratory supplies for research and diagnostics. The CRO Service segment caters to clients needing specialized analytical services for drug development. The Research segment develops proprietary therapeutics that may be licensed or sold to partners in the pharmaceutical sector. ABION's revenue streams are derived from direct sales of reagents and services, as well as potential future licensing agreements from its research pipeline. ABION's business model integrates product sales, CRO services, and R&D activities to address multiple needs within the biopharmaceutical value chain. The company's diagnostic reagents and research reagents are sold directly to laboratories and research institutions. The CRO services are contracted by biopharmaceutical companies for specialized testing during drug development. The Research segment's focus on protein, nucleic acid, and antibody therapeutics positions ABION to develop novel treatments for incurable diseases, with commercialization opportunities through partnerships or direct sales. Abion is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Abion's Return on Capital Employed (ROCE)

Abion's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Abion's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Abion's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Abion’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Abion stock

Return on Capital Employed (ROCE) of Abion is -34.82 % in 2025.

Return on Capital Employed (ROCE) of Abion changed from -143.11 % to -34.82 %, representing a -75.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Abion since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Abion with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Abion

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Abion